期刊文献+

lncRNA ABHD11-AS1在宫颈癌中的表达及其临床意义 被引量:5

Expression and clinical significance of long non-coding RNA ABHD11-AS1 in cervical cancer
下载PDF
导出
摘要 目的:探讨长链非编码lncRNA ABHD11-AS1在宫颈癌中的表达及其与患者诊断及预后的关系。方法:采用实时荧光定量PCR检测方法,检测50例宫颈癌患者的血液标本及对照组中lncRNA ABHD11-AS1的表达水平,同时分析lncRNA ABHD11-AS1的相对表达量与宫颈癌患者诊断、临床病理特征及预后的关系。结果:lncRNA ABHD11-AS1在宫颈癌患者血液标本及对照组中的相对表达水平分别为(1.80±0.11)和(1.17±0.08),差异有统计学意义(P<0.05)。lncRNA ABHD11-AS1的表达水平与宫颈癌患者的淋巴结转移,淋巴管血管侵袭、肿瘤大小及FIGO分期有关(P<0.05),而与患者的年龄、绝经情况等均无关,同时ROC显示lncRNA ABHD11-AS1作为宫颈癌标志物具有一定的诊断意义。与lncRNA ABHD11-AS1低表达组比较,lncRNA ABHD11-AS1高表达组患者的中位OS明显缩短(P<0.05)。结论:lncRNA ABHD11-AS1在宫颈癌中的表达水平升高,lncRNA ABHD11-AS1可以作为判断宫颈Ca预后的分子标志物。 Objective:To investigate the expression of the long non-coding RNA(lncRNA)ABHD11-AS1 in cervical cancer and its association with diagnosis and prognosis.Methods:Quantitative real-time PCR was used to measure the expression level of lncRNA ABHD11-AS1 in blood samples of 50 patients with cervical cancer and the subjects in the control group,and the association of the relative expression level of lncRNA ABHD11-AS1 with the diagnosis,clinicopathological features,and prognosis of cervical cancer patients was analyzed.Results:There was a significant difference in the relative expression level of lncRNA ABHD11-AS1 in blood samples between the patients with cervical cancer and the control group(1.80±0.11 vs 1.17±0.08,P<0.05).The expression level of lncRNA ABHD11-AS1 was associated with lymph node metastasis,lymphatic vessel invasion,tumor size,and FIGO stage in patients with cervical cancer(P<0.05),while it was not associated with patients’age and menopause status.The receiver operating characteristic curve analysis showed that lncRNA ABHD11-AS1 had certain diagnostic significance as a marker for cervical cancer.Compared with the low lncRNA ABHD11-AS1 expression group,the high lncRNA ABHD11-AS1 expression group had a significantly shorter median OS(P<0.05).Conclusion:The expression of lncRNA ABHD11-AS1 is upregulated in cervical cancer,and lncRNA ABHD11-AS1 can be used as a potential molecular marker for diagnosis and prognosis.
作者 黄晶 林也容 李娟 HUANG Jing;LIN Yierong;LI Juan(Departnent of Clinical Medicine,Gynecology and Surgery in Zhangzhou Health Uocational College,Zhangzhou 363000 Fujian Province,China;Department of Obstetrics and Gynecology,in the Affiliated Dongnan Hospital of Xiamen University;Department of Obstetrics and Gynecology,in the Xiangcheng Maternal and Child Health Hospital of Zhangzhou)
出处 《西南医科大学学报》 2020年第1期24-27,31,共5页 Journal of Southwest Medical University
关键词 IncRNA ABHD11-ASI宫颈癌 表达 临床意义 Cervical cancer Expression Clinical significance
  • 相关文献

参考文献1

二级参考文献160

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CACancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166].
  • 2Costello E, Greenhalf W, Neoptolemos JP. New biomarkers andtargets in pancreatic cancer and their application to treatment. NatRev Gastroenterol Hepatol 2012; 9: 435-444 [PMID: 22733351DOI: 10.1038/nrgastro.2012.119].
  • 3Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N,Macdonald JS, Somerfield MR, Hayes DF, Bast RC. ASCO2006 update of recommendations for the use of tumor markers ingastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327 [PMID:17060676 DOI: 10.1200/jco.2006.08.2644].
  • 4Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, AndersonMA, Bamberger AM, Greenson J, Brand RE, Ramachandran V,Logsdon CD. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007; 34: 436-443 [PMID: 17446843 DOI:10.1097/MPA.0b013e3180333ae3].
  • 5Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM,Goldenberg DM. New MUC1 serum immunoassay differentiatespancreatic cancer from pancreatitis. J Clin Oncol 2006; 24:252-258 [PMID: 16344318 DOI: 10.1200/jco.2005.02.8282].
  • 6Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H,Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y,Yamao K. Serum tumor antigen REG4 as a diagnostic biomarker inpancreatic ductal adenocarcinoma. J Gastroenterol 2010; 45: 52-59[PMID: 19789838 DOI: 10.1007/s00535-009-0114-y].
  • 7Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, GoldbergM, Elton E, Arnoletti JP, Christein JD, Vickers SM, LangmeadCJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE.Serum biomarker panels for the detection of pancreatic cancer.Clin Cancer Res 2011; 17: 805-816 [PMID: 21325298 DOI:10.1158/1078-0432.CCR-10-0248].
  • 8He XY, Liu BY, Yao WY, Zhao XJ, Zheng Z, Li JF, Yu BQ, YuanYZ. Serum DJ-1 as a diagnostic marker and prognostic factor forpancreatic cancer. J Dig Dis 2011; 12: 131-137 [PMID: 21401899DOI: 10.1111/j.1751-2980.2011.00488.x].
  • 9Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in theserum of cancer patients and the effect of therapy. Cancer Res1977; 37: 646-650 [PMID: 837366].
  • 10Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, YaoSL. Soluble normal and mutated DNA sequences from single-copygenes in human blood. Cancer Epidemiol Biomarkers Prev 1994; 3:67-71 [PMID: 8118388].

共引文献7

同被引文献33

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部